Ronald T. Ackermann, MD, MPH

home / authors / ronald-t-ackermann-md-mph

Articles

December 12th 2023

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

David T. Liss, PhD Manisha Cherupally, MS Matthew J. O’Brien, MD, MSc Raymond H. Kang, MA Cassandra Aikman, MPH Amisha Wallia, MD, MS Andrew J. Cooper, MSc Eleena Koep, MS Emily D. Parker, PhD, MPH Ronald T. Ackermann, MD, MPH

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

March 9th 2021

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

David T. Liss, PhD Raymond H. Kang, MA Nicola Lancki, MPH Matthew J. O’Brien, MD, MSc Amisha Wallia, MD, MS Andrew J. Cooper, MSc Sterling A. Harris, BA Emily D. Parker, PhD, MPH Ronald T. Ackermann, MD, MPH

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.

June 21st 2017

Comparative Effectiveness and Costs of Insulin Pump Therapy for Diabetes

Ronald T. Ackermann, MD, MPH Amisha Wallia, MD, MS Raymond Kang, MA Andrew Cooper, MPH Theodore A. Prospect, FSA, MAAA Lewis G. Sandy, MD, MBA Deneen Vojta, MD

Evaluation of healthcare utilization and costs over 3 years for adults with insulin-requiring diabetes who transition from multiple daily insulin injections to insulin infusion pumps.

March 13th 2013

Effectiveness and Cost-Effectiveness of Diabetes Prevention Among Adherent Participants

William H. Herman, MD, MPH Sharon L. Edelstein, ScM Robert E. Ratner, MD Maria G. Montez, RN, MSHP Ronald T. Ackermann, MD, MPH Trevor J. Orchard, MD Mary A. Foulkes, PhD Ping Zhang, PhD Christopher D. Saudek, MD&dagger Morton B. Brown, PhD The Diabetes Prevention Program Research Group

Over 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.